A recent application from CB Therapeutics on biosynthetic psilocybin is emblematic of the IP concerns around novelty and obviousness the psychedelic field will face.
Two weeks ago, German microbiologist Felix Blei received a barrage of messages, all telling him to look up a patent application filed by CB Therapeutics, a psychedelics company.
The application, published on May 20, was originally filed on November 15, 2019. (Patent applications are kept secret for 18 months.) First reported by Psilocybin Alpha, the application has claims on organisms genetically modified to produce psilocybin by giving them the genes for enzymes that make the compound naturally in mushrooms.
Read more at